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ABSTRACT
Despite rare reports of Type I Hypersensitivity reactions (anaphylaxis) to colloid plasma expanders, they find wide application during 
resuscitation and major surgeries. We present the case of a possible Type I hypersensitivity reaction to Gelofusine® in a 42-year-old 
female patient during oncological surgery. The delayed manifestation caused some diagnostic confusion with an embolic event. The 
patient was symptomatically treated and the rest of the surgery was completed uneventfully. A high index of suspicion is vital for 
prompt identification and treatment of anaphylaxis.
Keywords: Gelofusine, Hypersensitivity reaction, Skin prick test.
Allogenic blood transfusion has been implicated in cancer recurrence [1]. Synthetic colloids are a viable option for perioperative volume resuscitation when blood loss 
is within the acceptable range. Among the products available 
Gelofusine® is extremely popular [2]. Though Gelofusine® has 
the potential to cause anaphylaxis, the incidence is rare (6.2 in 
100,000) [3]. We, as perioperative physicians quickly resort 
to its use to swiftly correct intraoperative hypovolemia. The 
rationale of this case report is to remind anaesthesiologists that 
hypersensitivity to Gelofusine® is a reality.  It can have an atypical 
presentation and cause diagnostic confusion with embolism.
CASE REPORT
A 42-year-old female patient diagnosed with adenocarcinoma 
of the ovary, post 6 cycles of chemotherapy was scheduled 
for delayed cytoreductive surgery. Preoperative workup was 
within an acceptable range. There was a previous history of an 
uneventful surgery under general anesthesia (GA) following a 
road traffic accident. 
On the day of surgery, standard monitors were applied and 
an epidural catheter inserted in the T9-10 interspace. GA was 
induced with intravenous (IV) fentanyl 90mcg, propofol 100mg 
and vecuronium 5mg at 9.30 am. After a negative intradermal test 
dose, IV Cefuroxime 1.5 gm was administered before the skin 
incision and 0.125% bupivacaine epidural infusion was initiated. 
The patient remained hemodynamically stable for 2.5 hours with 
a blood loss of 500ml. After administration of 2L crystalloids, 
Gelofusine® (B. Braun, manufacture date- 11.2017, expiry- 
10.2020, LOT no- 17462362) was started at 11.55 am. After 27 
minutes, when >150ml of Gelofusine® had already been infused, 
the patient’s blood pressure and saturation began to drop with the 
rise in peak airway pressure (Fig. 1). The sudden decrease in the 
end-tidal CO2 (ETCO2) along with the other signs misled us into 
assuming the event to be embolic. 
Since we did not suspect a reaction to Gelofusine®, the 
remaining colloid was infused and the patient was started on a 
noradrenaline infusion. Meanwhile, her upper extremity was 
exposed in order to insert an arterial line. Mottling of the skin in 
both upper limbs was noticed at this point. The hemodynamics 
also responded to a bolus of IV adrenaline 20 µg. Hence, we 
started an adrenaline infusion of 0.2 µg/kg/hr and gradually her 
blood pressure stabilized. 
A central venous catheter was inserted under ultrasound 
(USG) guidance for the administration of the vasoactive 
infusions. Surgery was completed and the patient shifted to 
the intensive care unit (ICU) for elective ventilation. Bedside 
echocardiogram (ECHO) and 12 lead electrocardiogram (ECG) 
were found normal, excluding the possibility of an embolic 
episode. Due to non-availability, serum tryptase levels were not 
Figure 1: intraoperative events (MAP=mean arterial pressure, 
PAW=peak airway pressure, ETCO2=end-tidal CO2, SpO2=oxygen 
saturation).
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determined. The patient was weaned off from the vasopressors in 
3 hours, extubated in 6 hours and shifted out of ICU in 2 days. 
A week later, just before her discharge, an intradermal test was 
performed after informed consent. A skin bleb with a diameter of 
0.7mm was raised by injecting 0.05 ml of Gelofusine®. The wheal 
increased to 1.5mm after 15 minutes (<3mm increase in size is 
considered positive). This modest response was probably due to 
mast cell depletion which is likely to occur when the allergen 
test is performed in less than 4 weeks of anaphylaxis [4]. Type 
I hypersensitivity reaction to Gelofusine® was the most likely 
cause of the hemodynamic instability in our patient. The patient 
was uneventfully discharged on the 10th postoperative day and 
was informed of her allergy to Gelofusine®. The same details 
were also entered in her medical records.
DISCUSSION
Gelofusine® is succinylated gelatin, supplied in 500ml 
biocompatible containers and acts as a plasma expander for 1-2 
hours. Its use in the perioperative period is increasing especially 
in oncological surgery where allogeneic blood transfusion is 
associated with an increased incidence of cancer recurrence 
[1]. In a recent multinational trial, succinylated gelatins were 
the second most common colloid used after albumin [2]. 
According to the allergen survey 6th National Audit Project 
conducted by Royal College of Anesthetists, the annual 
exposure rate to gelatin-based solutions during surgery in the 
UK is 1.7% i.e. 48203 patients while the calculated incidence 
of severe anaphylaxis is 6.2 per 100000, a rate similar to that of 
rocuronium [3]. 
Zhu et al in their article expressed that succinylated gelatin 
allergy, which is IgE antibody-mediated has no relation to either 
age or sex but there’s an association with pre-existing penicillin 
and animal protein allergy. The allergic reaction usually occurs 
intraoperatively with 169.7 ± 104.1ml infusion over an interval 
of 11.78 ± 11.47 min [5].
Perioperative anaphylaxis detection is always a challenge 
and Rose et al propose a comprehensive classification that 
will help guide the clinician to identify severe anaphylaxis and 
treat the patient with the correct adrenaline dose [6] (Table 
1). Perioperative anaphylaxis can have a wide spectrum of 
symptoms and signs. Our patient had a sudden elevation of the 
peak airway pressure followed by hypotension and precipitous 
fall in ETCO2. Given the situation of a pelvic malignancy treated 
with chemotherapy, these signs initially raised the suspicion of 
pulmonary embolism [7].
Hypotension, tachycardia, fall in saturation and ETCO2 are 
the commonest signs of pulmonary embolism during a general 
anesthetic [8]. The incidence of perioperative pulmonary 
embolism in gynecological malignancies is reported to be 
0.3%-4.1% [9]. Thus, the remaining Gelofusine® was given 
for volume resuscitation. To add to the confusion was that 
the upper part of the body was covered by surgical drapes and 
there was a latency period for the reaction. The initial inotrope 
started was noradrenaline but the poor response prompted us to 
administer an adrenaline bolus which produced hemodynamic 
Grade A Grade B Grade C
Moderate perioperative anaphylaxis
Life-threatening perioperative 
anaphylaxis
Cardiac arrest with or without respiratory 
arrest associated with perioperative 
anaphylaxis
Measurable derangements in one or more major organ 
systems The derangements are unexpected for the stage of 
the patient’s perioperative course Non-life-threatening
Life-threatening cardiovascular or 
respiratory derangement, or both
Cardiac or respiratory arrest, or both
Cardiovascular system
(i)   Hypotension
(ii)  Tachycardia or bradycardia
(iii) Arrhythmia
Cardiovascular system
(i)  Systolic blood pressure of <60 
mm Hg
(ii) Life-threatening tachy- or 
bradyarrhythmia
Cardiovascular system
(i) Cardiac arrest
Respiratory system
(i)   Cough
(ii)  Wheeze
(iii) Difficult ventilation
(3) Oxygen desaturation
(3)  Difficulty swallowing
Rhinorrhoea
Respiratory system
(i)   Oxygen saturation <90%
(ii)  Inspiratory pressures of >40 cm 
H2O
(iii) Severe difficulty inflating the 
lungs
(3) Airway angioedema
Respiratory system
(i) Respiratory arrest or complete failure of 
ventilation
Other systems
(i)   Unexpected change in consciousness
(ii)  Agitation
(iii) Gastrointestinal upset
Cutaneous signs (e.g. flushing, urticaria, angioedema) may or may not be present. At least one other system is involved for the diagnosis
Table 1: Perioperative Anaphylaxis Grading System (6)
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stability. This raised the clinical suspicion of an allergic reaction 
to Gelofusine® as no new drug had been administered in the last 
30 min.  
Most case reports of anaphylaxis to Gelofusine® mention 
serum tryptase levels and/or skin prick test/intradermal test 
to establish the diagnosis [4, 10-12]. An increase in serum 
tryptase at the time of reaction above 1.2 × baseline +2 µg/L 
is considered clinically relevant [13]. The basophil activation 
test is an in-vitro assay to predict or confirm sensitivity to 
Gelofusine® [14]. Performance and interpretation of the tests 
are well elucidated in a recent article by Farooque et al, which 
we used as a guide [12]. 
Skin prick testing is performed with undiluted or 1:10 
diluted allergen. A wheel diameter of ≥ 3 mm at 15 min is 
considered positive along with the relevant clinical history. If 
the skin prick test is negative or inconclusive, the intradermal 
test on the forearm is performed with increasing concentrations 
of the allergen from a dilution of 1 in 10,000 to undiluted 
allergen.  A bleb of 4–6 mm is raised by injecting 0.03–0.05 
ml and a wheel diameter of < 3 mm larger than the negative 
control at 20 min is considered positive. If the intradermal 
test is also negative then an intravenous test is performed in 
controlled conditions [12].
Though rare, Gelofusine® has the potential to cause a 
severe anaphylactic reaction with a variable latency period and 
presentation intraoperatively. It has the unusual distinction of 
causing the same hypotension it is used to treat. It may be well 
worth periodically examining the patient under the drapes once 
Gelofusine® infusion is initiated and watch out for unexplained 
respiratory and hemodynamic changes. 
CONCLUSION
It is prudent to restrict the use of Gelofusine® to compelling 
circumstances and exercise caution while using it. Unexplained 
decompensation associated with Gelofusine® administration 
should be regarded with a high index of suspicion.
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